Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2023-186284

Published: 2023

Journal Articles

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Ryan Jacobs, Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frédéric Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda Wu, Zaina P. Qureshi, Moshe Yair Levy

Blood (2022) 140 (Supplement 1): 1931–1933.

https://doi.org/10.1182/blood-2022-163387

Published: 2022

Journal Articles

Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Kerry Rogers, Bruno Emond, Aurélie Côté-Sergent, Frédéric Kinkead, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang

Blood (2021) 138 (Supplement 1): 4030.

https://doi.org/10.1182/blood-2021-148575

Published: 2021

Journal Articles

Patient Characteristics, Treatment Patterns and Outcomes Among Black and White Patients with Multiple Myeloma Initiating Daratumumab: A Real-World Chart Review Study

Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray, Isabelle Ghelerter, Marie-Hélène Lafeuille, Patrick Lefebvre, Adriana C Rossi

Blood (2021) 138 (Supplement 1): 1965.

https://doi.org/10.1182/blood-2021-145941

Published: 2021

Journal Articles

Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Anna Narezkina, Xiaoxiao Lu, Bruno Emond, Aurélie Côté-Sergent, Annalise Hilts, Stephanie Liu, Marie-Hélène Lafeuille, Patrick Lefebvre, Qing Huang

Blood (2021) 138 (Supplement 1): 4112.

https://doi.org/10.1182/blood-2021-148640

Published: 2021

Journal Articles

Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels

Alok A Khorana, MD, Keith R McCrae, MD, Nicole M. Kuderer, Dejan Milentijevic, François Laliberté, Guillaume Germain, MSc, Sean D. MacKnight, Patrick Lefebvre, Gary H. Lyman, MD MPH, Michael B. Streiff, MD

Blood (2019) 134 (Supplement_1): 1143.

https://doi.org/10.1182/blood-2019-129090

Published: 2019

Journal Articles

The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Alok A. Khorana, MD, Nicole M. Kuderer, MD, Keith R. McCrae, MD, Dejan Milentijevic, PhD, Guillaume Germain, MA, François Laliberté, MA, Nguyen Le, BSc, Patrick Lefebvre, MA, Gary H. Lyman, MD MPH, FRCP, Michael B. Streiff, MD

Blood (2018) 132 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2018-99-116224

Published: 2018

Journal Articles

Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Michael B. Streiff, MD, Keith R. McCrae, MD, Nicole M. Kuderer, MD, Dejan Milentijevic, PhD, Guillaume Germain, MA, François Laliberté, MA, Nguyen Le, BSc, Patrick Lefebvre, MA, Gary H. Lyman, MD MPH, FRCP, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 3799.

https://doi.org/10.1182/blood-2018-99-117121

Published: 2018

Journal Articles

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Song Wang, PhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA, Murali Sundaram, MBA, PhD, Anthony R Mato, MD

Blood (2018) 132 (Supplement 1): 2306.

https://doi.org/10.1182/blood-2018-99-116473

Published: 2018

Journal Articles

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Murali Sundaram, MBA, PhD, Marie-Hélène Lafeuille, MA, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 5600.

https://doi.org/10.1182/blood.V130.Suppl_1.5600.5600

Published: 2017

Journal Articles

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

Bruce L. Davidson, MD MPH, Philip S. Wells, MD FRCPC, MSc, Martin H. Prins, MD PhD, Jan Beyer-Westendorf, MD, Anthonie WA. Lensing, MD PhD, Lloyd Haskell, MD, Bennett Levitan, MD PhD, François Laliberté, Veronica Ashton, MPH, Yongling Xiao, PhD, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, MA, Qi Zhao, MPH, Zhong Yuan, MD PhD, Jeff Schein, Paolo Prandoni, MD PhD

Blood (2017) 130 (Supplement 1): 218.

https://doi.org/10.1182/blood.V130.Suppl_1.218.218

Published: 2017

Journal Articles

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Alok A. Khorana, MD, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Michael B. Streiff

Blood (2017) 130 (Supplement 1): 4631.

https://doi.org/10.1182/blood.V130.Suppl_1.4631.4631

Published: 2017

Journal Articles

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Marie-Hélène Lafeuille, MA, Murali Sundaram, MBA, PhD, Daniela Hoehn, MDPhD, Bruno Emond, MSc, Hela Romdhani, PhD, Patrick Lefebvre, MA

Blood (2017) 130 (Supplement 1): 4714.

https://doi.org/10.1182/blood.V130.Suppl_1.4714.4714

Published: 2017

Journal Articles

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Michael B. Streiff, Keith McCrae, MD, Dejan Milentijevic, Nora McCormick, François Laliberté, Concetta Crivera, Patrick Lefebvre, MA, Dominique Lejeune, Heather Rozjabek, Jeff Schein, Alok A. Khorana, MD

Blood (2017) 130 (Supplement 1): 4640.

https://doi.org/10.1182/blood.V130.Suppl_1.4640.4640

Published: 2017

Journal Articles

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Alok A. Khorana, MD, Jeffrey S Berger, MD, Philip S Wells, MD, Roger Seheult, MD, Veronica Ashton, MPH, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Dominique Lejeune, MA, Jeff Schein, DrPH, MPH, Peter Wildgoose, PhD, Patrick Lefebvre, MA, Scott Kaatz, DO, MSc

Blood (2016) 128 (22): 144.

https://doi.org/10.1182/blood.V128.22.144.144

Published: 2016

Journal Articles

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

Michael Streiff, MD, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie Nelson, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 1178.

https://doi.org/10.1182/blood.V128.22.1178.1178

Published: 2016

Journal Articles

VTE-Related Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Michael Streiff, MD, Dejan Milentijevic, Keith R. McCrae, MD, Jonathan Fortier, François Laliberté, MA, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH, Alok A. Khorana, MD

Blood (2016) 128 (22): 3524.

https://doi.org/10.1182/blood.V128.22.3524.3524

Published: 2016

Journal Articles

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Alok A. Khorana, MD, Keith R. McCrae, MD, Dejan Milentijevic, Jonathan Fortier, François Laliberté, MA, Concetta Crivera, PharmD, MPH, Patrick Lefebvre, MA, Jeff Schein, DrPH, MPH

Blood (2016) 128 (22): 4734.

https://doi.org/10.1182/blood.V128.22.4734.4734

Published: 2016

Journal Articles

Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Alok A. Khorana, MD, Keith McCrae, Dejan Milentijevic, Jonathan Fortier, Winnie Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Daniel Yannicelli, Jeff Schein

Blood (2015) 126 (23): 626.

https://doi.org/10.1182/blood.V126.23.626.626

Published: 2015

Journal Articles

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Blood (2013) 122 (21): 3178.

https://doi.org/10.1182/blood.V122.21.3178.3178

Published: 2013

NARROW

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib

Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Patient Characteristics, Treatment Patterns and Outcomes Among Black and White Patients with Multiple Myeloma Initiating Daratumumab: A Real-World Chart Review Study

Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Cancer Associated Thrombosis Is Associated with Higher Mortality across All Khorana Score Risk Levels

The Rate of Venous Thromboembolism in Cancer Patients Varies By Khorana Risk Category

Healthcare Costs in Patients with Cancer Increase with Increasing Risk of Venous Thromboembolism

Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia

Treatment Patterns of Hypomethylating Agents in Older (≥65 Years) Acute Myeloid Leukemia Patients Who Did Not Receive Intensive Chemotherapy: A Retrospective Claims Database Analysis

Healthcare Cost Impact of Continued Anticoagulation Therapy with Rivaroxaban Versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the Einstein Choice Trial Population

VTE Recurrence and Safety of Anticoagulants Among Patients with Cancer Treated for Venous Thromboembolism

Managing Acute Myeloid Leukemia in Older Patients: Are We Making Progress? An Analysis of Treatment Patterns and Healthcare Resource Utilization

Healthcare Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Risk of Venous Thromboembolism Recurrence Among Rivaroxaban Treated Patients Who Continued Versus Discontinued Therapy: Analyses Among VTE Patients

Safety of Anticoagulant Therapies for Treatment of Venous Thromboembolism in Patients with Cancer

VTE-Related Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism in Cancer Patients Treated with Anticoagulants

Healthcare Resource Utilization and Costs Associated with Venous Thromboembolism Recurrence in Patients with Cancer

Current Practice Patterns and Patient Persistence on Anticoagulant Treatments for Cancer-Associated Thrombosis

Comparable Outcomes With Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only